Clinical Experience With Lamivudine

ABSTRACT

Lamivudine, an oral nucleoside analogue, has demonstrated efficacy against the hepatitis B virus (HBV) in both HBeAg-positive and HBeAg-negative patients with chronic hepatitis B. Treatment with lamivudine is safe and well tolerated and induces a virological and biochemical response in most patients within a short time. Significant histological improvement was seen in clinical trials after 52 weeks of lamivudine treatment. However, durable posttreatment remission of chronic hepatitis B has not been shown to occur in a significant number of lamivudine-treated patients. To maintain the response to treatment, therefore, long-term therapy is required. Prolongation of therapy, however, is associated with the emergence of HBV resistance to lamivudine in most patients. This is accompanied by virological rebound and reversal of the initial therapeutic response, and sometimes by exacerbation of hepatitis. The need remains for effective, safe, and tolerable oral agents with durable activity against HBV.

KEYWORDS

Hepatitis - chronic hepatitis B - lamivudine - nucleoside analogues - antiviral resistance

REFERENCES

• 1 Complete prescribing information for Epivir-HBV (lamivudine). Research Triangle Park, NC: GlaxoSmithKline; 2001 . 
• 2 Doong S L, Tsai C H, Schinazi R F. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues.  Proc Natl Acad Sci U S A . 1991;  88 8495-8499
• 3 Dienstag J L, Schiff E R, Wright T L. Lamivudine as initial therapy for chronic hepatitis B in the United States.  N Engl J Med . 1999;  341 1256-1263
• 4 Lai C L, Chien R N, Leung N W. A one-year trial of lamivudine for chronic hepatitis B.  N Engl J Med . 1998;  339 61-68
• 5 Schiff E, Karayalcin S, Grimm R. A placebo-controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy (Abst).  Hepatology . 1998;  28(Suppl) 388A
• 6 Knodell R G, Ishak K G, Black W C. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.  Hepatology . 1981;  1 431-435
• 7 Liaw Y F, Leung N W, Chang T T. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.  Gastroenterology . 2000;  119 172-180
• 8 Leung N W, Lai C L, Chang T T. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology . 2001;  33 1527-1532
• 9 Liaw Y F, Chien R N, Yeh C T. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.  Hepatology . 1999;  30 567-572
• 10 Liaw Y F. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.  Antivir Chem Chemother . 2000;  12(Suppl) 67-71
• 11 Lau D TY, Khokhar F, Doo E. Long-term therapy of chronic hepatitis B with lamivudine.  Hepatology . 2000;  32 828-834
• 12 Tassopoulos N C, Volpes R, Pastore G. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.  Hepatology . 1999;  29 889-896
• 13 Santantonio T, Mazzola M, Iacovazzi T. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis treated for 12 months with lamivudine.  J Hepatol . 2000;  32 300-306
• 14 Rizzetto M, Santantonio T, Buti M. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B (CHB) (Abst).  Hepatology . 2000;  32 459A
• 15 Cho S W, Hahm K-B, Kim J H. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.  Hepatology . 2000;  32 1163-1169
• 16 Hadziyannis S J, Papatheodoridis G V, Dimou E. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.  Hepatology . 2000;  32 847-851
• 17 Tassopoulos N C, Anagnostopoulos G D. Long-term lamivudine treatment of patients with precore mutant profile [HBeAg(-)/antiHBe(+)] chronic hepatitis B (Abst).  Antivir Ther . 2000;  5(Suppl) 34
• 18 Esteban R, Goldin R D, Tassopoulos N C. Clinical and histological outcome of extended lamivudine in patients with HBeAg-negative chronic hepatitis B (Abst).  Hepatology . 2001;  34 446A
• 19 Lok A S, Hussain M, Cursano C. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.  Hepatology . 2000;  32 1145-1153
• 20 Liu C J, Chen P J, Lai M Y. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences.  Hepatology . 2001;  34 583-589
• 21 Seehofer D, Rayes N, Steinmuller T. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.  Liver Transpl . 2001;  7 976-982
• 22 Schvoerer E, Kabissa I, Cotto E. Lamivudine therapy of chronic hepatitis B in three groups of patients: nontransplanted patients, liver recipients, and kidney recipients.  Gastroenterol Clin Biol . 2002;  26 62-66
• 23 Bock C T, Tillmann H L, Torresi J. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.  Gastroenterology . 2002;  122 264-273
• 24 Dore G J, Cooper D A, Barrett C. Dual efficacy of lamivudine treatment in human immunodeficiency virus/ hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR).  J Infect Dis . 1999;  180 607-613
• 25 Benhamou Y, Bochet M, Thibault V. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.  Hepatology . 1999;  30 1302-1306
• 26 Liaw Y F. Management of patients with chronic hepatitis B.  J Gastroenterol Hepatol . 2002;  17 406-408
• 27 Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy.  J Gastroenterol Hepatol . 2002;  17 409-414